Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?
Roberto LatagliataMassimo BrecciaIda CarmosinoLaura CesiniDaniela De BenedittisSara MohamedFederico VozellaMatteo MolicaMelissa CampanelliMaria Lucia De LucaGioia ColafigliLuisa QuattrocchiMaria Giovanna LoglisciFulvio MassaroMartina CanichellaDaniela DiverioMarco ManciniGiuliana AlimenaRobin FoàPublished in: European journal of haematology (2018)
Age at diagnosis influences significantly the course of CML patients treated with imatinib: a possible explanation of the counterintuitive worse course in YA is the delayed diagnosis compared to elderly.
Keyphrases